Who we are

We are an immuno-oncology company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives.

Our technology

Our pioneering T-LITE™ platform provides switchable activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing.